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SUMMARY
Metastatic spinal cord compression, a term normally including compression of the spinal cord or 
nerve roots running within the spinal canal, is a common complication of systemic cancer, occurring 
in 5–10% of all patients with cancer. Recent published data on treatment of metastatic spinal cord 
compression (MSCC) have shown that radiotherapy (RT) alone is an effective approach for the major-
ity of cases. Except for some protocols, the use of conventional RT (daily fractions of 2 Gy to a total 
dose of 30–40 Gy) has been abandoned in favour of radiation treatment regimens requiring a smaller 
number of fractions. In some published trials, 4–5 Gy daily for 8 days followed by 4 days rest, and 
then 5–16 daily doses of 2–3 Gy have been given with both good results and tolerance. Higher daily 
fractions ranging from 6 to 10 Gy have also been explored with similar results.    
We have summarized the studies comparing the treatments and clinical outcome. Most patients with 
MSCC have a life expectancy of only several months. In these patients one radiotherapeutic schedule 
with a short overall treatment time would be the best option, if its effect on the most relevant clinical 
symptoms, pain and motor dysfunction, is comparable to the effect of more protracted schedules. 
In patients with a reduced life expectancy, a radiotherapeutic effect on recalcifi cation, which can be 
expected only several months after RT, is of minor importance. In patients with a life expectancy of 
more than a few months, recalcifi cation becomes more of an issue and a more fractionated radiation 
schedule should be considered.
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INTRODUCTION
Metastatic spinal cord compression, a term 
normally including compression of the spinal 
cord or nerve roots running within the spinal 
canal, is a common complication of systemic 
cancer, occurring in 5-10% of all patients 
with cancer. The prognosis is infl uenced by 
many factors, and large retrospective studies 
comprising more than 150 patients as well as 
studies comprising fewer patients have tried 
to evaluate the prognostic signifi cance of dif-
ferent clinical and radiological variables pres-
ent at the time of diagnosis. Both prospective 
and retrospective studies agree that the most 
effective management of an epidural metasta-
sis is to initiate treatment before neurological 
defi cits develop.
Surgery (i.e. compressive laminectomy) 
plus radiotherapy (RT) or RT alone are both 
good strategies, provided they are performed 
early. Because the success of treatment is re-
lated to the severity of the epidural disease 
and clinical condition at the time of diagno-
sis, it is important to perform diagnosis early 
and to begin treatment before signifi cant my-
elopathy develops. A tendency to prefer RT 
rather than surgery has emerged over the 
last years in view of its greater feasibility. In 
fact, surgery results in 3–14% mortality and 
5–30% morbidity rate and the wound con-
fi nes the patients to bed for a certain period. 
Generally, laminectomy does not remove the 
neoplastic mass and, when there is vertebral 
body collapse, it may also cause post-surgery 
spinal instability. Recent trials indicate that 
simple laminectomy should be abandoned in 
favour of a more aggressive approach (i.e. 
posterior, anterior, or lateral decompression, 
plus stabilization of the spine). This special 
complex technique is advised in selected 
cases as follows: (a) if there are diagnostic 
doubts; (b) if stabilization is necessary; (c) if 
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RT has already been given in the same area; 
(d) when vertebral body collapse causes bone 
impingement on the cord or nerve roots. In 
all other cases RT alone can give the same 
results as surgery plus RT, and it does not 
cause remarkable morbidity.
Recent published data on treatment of 
metastatic spinal cord compression (MSCC) 
have shown that radiotherapy (RT) alone is an 
effective approach for the majority of cases. 
Nevertheless, the optimal radiation schedule 
is unknown [3]. Except for some protocols, the 
use of conventional RT (daily fractions of 2 Gy 
to a total dose of 30 – 40 Gy) has been aban-
doned in favour of radiation treatment regi-
mens requiring a smaller number of fractions. 
In some published trials, 4 – 5 Gy daily for 8 
days followed by 4 days rest, and then 5 – 16 
daily doses of 2 – 3 Gy have been given with 
both good results and tolerance. Higher daily 
fractions ranging from 6 to 10 Gy have also 
been explored with similar results. The pur-
pose of this review was to assess the clinical 
outcome and toxicity of various fractionated 
regimes in MSCC.
Fractionation for radiotherapy of MSCC:
Rades et al. (2002) investigated the prognos-
tic value of the time of motor defi cit develop-
ment before radiotherapy (RT). Ninety-eight 
patients were included between November 
1998 and April 2000. Three subgroups were 
formed, according to time of motor defi cit de-
velopment before RT: 1 – 7 days (n = 31), 8 
– 14 days (n=31) and > 14 days (n = 36). Am-
bulatory rates and motor function were evalu-
ated for < 24 weeks after RT. In a multivari-
ate analysis, all three prognostic factors and 
radiation parameters were included. In the > 
14 days subgroup, improvement occurred sig-
nifi cantly (p < 0.001) more often than in the 
other subgroups (86% vs 29% and 10%) and 
the post-treatment ambulatory rate was sig-
nifi cantly higher (86% vs. 55% and 35%, p = 
0.026). Multivariate analysis revealed the time 
of development of motor defi cits before RT to 
be the strongest prognostic factor. Functional 
outcome is signifi cantly better with slower de-
velopment of motor defi cits before RT. This 
new, independent prognostic factor must be 
considered in future trials aiming to defi ne an 
optimal RT schedule.
Larsen et al. (2000) analyzed the prognostic 
signifi cance of various clinical and radiologi-
cal variables on post-treatment ambulatory 
function and survival. During a 3½ year pe-
riod they prospectively included 153 consecu-
tive patients with a diagnosis of spinal cord 
compression due to metastatic disease. The 
patients were followed with regular neurologi-
cal examinations by the same neurologist for a 
minimum period of 11 months or until death. 
The prognostic signifi cance of fi ve variables 
on gait function and survival time after treat-
ment was analyzed. The type of the primary 
tumour had a direct infl uence on the interval 
between the diagnosis of the primary malig-
nancy and the occurrence of spinal cord com-
pression (p < 0.0005), and on the ambulatory 
function at time of diagnosis (p = 0.016). There 
was a clear correlation between the degree of 
myelographic blockage and gait function and 
sensory disturbances (p = 0.000). The fi nal 
gait was dependent on the gait function at time 
of diagnosis (p < 0.0005). Survival time after 
diagnosis depended directly on the time from 
primary tumour diagnosis until spinal cord 
compression (p = 0.002), on the ambulatory 
function at the time of diagnosis (p=0.018), 
and on the ambulatory function after treat-
ment. The pretreatment ambulatory function 
is the main determinant for post-treatment 
gait function. Survival time is rather short, es-
pecially in non-ambulatory patients, and can 
only be improved by restoration of gait func-
tion in non-ambulatory patients by immediate 
treatment.
Leviov et al. (1993) performed a retrospec-
tive analysis of 70 patients with this compli-
cation treated from 1985 to 1989. The most 
frequent primary diagnoses in their series 
were carcinomas of unknown origin and of 
the breast, lymphoproliferative disease, lung 
cancer, and prostatic carcinoma. They used 
the Findlay classifi cation to group all patients 
according to their pre-therapeutic functional 
motor status as Grade I (24 patients or 34%), 
grade II (27 or 39%) or grade III (19 or 27%). 
Treatment consisted of 30–45 Gy of irradiation 
(using two different schedules) together with 
high dose dexamethasone; in only fi ve cases 
was there surgical intervention. They found 
that a powerful predictor of response to radio-
therapy was the patient’s neurological status 
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(Findlay grade) at the time of diagnosis: 66% 
of previously ambulatory patients remained 
so, whereas 30% of non-ambulatory patients 
and only 16% of paraplegic patients regained 
the ability to walk. Another important predic-
tor of response was primary tumour histology, 
with the most favourable responses to radia-
tion therapy having been observed in lym-
phoproliferative diseases and in breast cancer, 
but with some response in other radiosensitive 
malignancies as well. The similarity of their 
results to those of other centres led them to 
conclude that a radiotherapeutic success ceil-
ing of 80% may have been reached for Findlay 
Grade I patients with metastatic spinal cord 
compression. In view of this, they suggested 
that future therapeutic endeavour would be 
best directed toward early diagnosis of the 
condition.
Maranzano and Latini (1995) performed a 
prospective trial in which patients with this 
complication were generally treated with RT 
plus steroids and surgery was reserved for 
selected cases. Two hundred and seventy-fi ve 
consecutive patients with MSCC entered this 
protocol. Twenty (7%) underwent surgery plus 
RT, and another 255 received RT alone. Of all 
eligible patients, 25 (10%) early deaths and 21 
(8%) entering a feasibility study of RT without 
steroids were not evaluable. Of the 209 evalu-
able cases, 110 were females and 99 males and 
median age was 62 years. Median follow-up 
was 49 months (range, 13 to 88) and treatment 
consisted of 30 Gy RT (using two different 
schedules) together with steroids (standard or 
high doses, depending on motor defi cit sever-
ity). Response was assessed according to back 
pain and motor and bladder function before 
and after therapy. Back pain total response 
rate was 82% (complete or partial response or 
stable pain, 54, 17 or 11%, respectively). About 
three-fourths of the patients (76%) achieved 
full recovery or preservation of walking 
ability and 44% with sphincter dysfunction 
improved. Early diagnosis was the most im-
portant response predictor so that a large ma-
jority of patients able to walk and with good 
bladder function maintained these capacities. 
When diagnosis was late, tumours with fa-
vourable histologies (i.e. myeloma, breast and 
prostate carcinomas) above all responded to 
RT. Duration of response was also infl uenced 
by histology. Favourable histologies are as-
sociated with higher median response (my-
eloma, breast and prostate carcinomas, 16, 12 
and 10 months, respectively). Median survival 
time was 6 months, with a 28% probability of 
survival for 1 year. Survival time was longer 
for patients able to walk before and/or after 
RT, those with favourable histologies and fe-
males. There was agreement between patient 
survival and duration of response, systemic 
relapse of disease being generally the cause 
of death. Early diagnosis of MSCC was a pow-
erful predictor of outcome. Primary tumour 
histology had weight only when patients were 
non-walking, paraplegic or had bladder dys-
function. The effectiveness of RT plus steroids 
in MSCC emerged in their trial. The most im-
portant factors positively conditioning their 
results were: the high rate of early diagnoses 
(52%) and the number of tumours with favour-
able histologies (124 out of 209, 63%) recruited 
and the choice of best treatment based on ap-
propriate patient selection for surgery and RT 
or RT alone.
Maranzano et al. (1997) evaluated the clini-
cal outcome and toxicity of a short-course 
regimen of radiotherapy (RT) in selected met-
astatic spinal cord compression (MSCC) pa-
tients. Between 1993 and 1995, 53 consecutive 
patients with MSCC from low radio-responsive 
primary tumours (non-small cell lung, kidney, 
head and neck and gastrointestinal carcino-
mas, melanoma and sarcomas) or more radio-
responsive ones (breast and prostate carcino-
mas, myeloma and lymphomas) with paresis, 
plegia, low performance status (PS ECOG ≥ 2) 
and/or short life expectation, underwent short-
course RT: a single fraction of 8 Gy repeated 
after 1 week in responders or stable patients, 
for a total dose of 16 Gy. Of 49 (92%) evaluable 
cases, 4 (8%) underwent surgery plus RT and 
the other 45 RT alone. Medium doses of paren-
teral dexamethasone (8 mg x 2/d) were given 
in all cases and precautionary anti-emetics to 
those treated with fi elds covering the upper 
abdomen (20 of 49 cases). Median follow-up 
was 25 months (range, 6–34). Response was 
assessed according to back pain and motor 
and bladder capacity before and after RT. Pain 
relief was achieved in 67% of patients and mo-
tor function response rate reached 63%. Early 
diagnosis and therapy were very important in 
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predicting response to RT; all but two (91%) 
pretreatment walking patients and all but one 
(98%) with good bladder function preserved 
these capacities. In contrast, when diagnosis 
was late, only 38% of non-ambulatory patients 
and 44% of those with bladder retention im-
proved. Median survival was 5 months, with a 
30% probability of survival for 1 year. Length 
of survival was signifi cantly longer for pa-
tients able to walk before and/or after RT. 
Good agreement between survival and dura-
tion of response was found with no evidence 
of relapse in the irradiated spine. Sickness ap-
peared only in a few cases. Slight oesophagitis 
was more frequent: dysphagia for solid foods 
in one-third of patients irradiated on the tho-
racic spine. Late toxicity was never recorded. 
The short-course RT adopted gave a clinical 
outcome comparable with that resulting from 
more protracted regimens with only slight 
side effects. The use of a few large treatment 
fractions could be explored considering the 
associated advantages for patients and radio-
therapy centres often overloaded by long pa-
tient waiting lists.
Maranzano et al. (2005) planned a random-
ized trial to assess the clinical outcome and 
toxicity of two different hypofractionated RT 
regimens in MSCC. Three hundred patients 
with MSCC were randomly assigned to short-
course RT (8 Gy x 2 days) or to split-course 
RT (5 Gy x 3; 3 Gy x 5). Only patients with 
a short life expectancy entered the protocol. 
Median follow-up was 33 months (range, 4 to 
61 months). A total of 276 (92%) patients were 
assessable: 142 (51%) treated with the short-
course and 134 (49%) treated with the split-
course RT regimen. There was no signifi cant 
difference in response, duration of response, 
survival or toxicity found between the two 
arms. When short- versus split-course regi-
mens were compared, after RT 56% and 59% 
of patients had back pain relief, 68% and 71% 
were able to walk and 90% and 89% had good 
bladder function, respectively. Median sur-
vival was 4 months and median duration of 
improvement was 3.5 months for both arms. 
Toxicity was equally distributed between the 
two arms: grade 3 oesophagitis or pharyngitis 
was registered in four patients (1.5%), grade 3 
diarrhoea occurred in four patients (1.5%) and 
grade 3 vomiting or nausea occurred in 10 pa-
tients (6%). Late toxicity was never recorded. 
Both hypofractionated RT schedules adopted 
were effective and had acceptable toxicity. 
However, considering the advantages of the 
short-course regimen in terms of patient con-
venience and machine time, it could become 
the RT regimen of choice in clinical practice 
for MSCC patients.
Rades (2002) compared three different 
schedules for functional outcome. For post-
treatment functional and ambulatory out-
come, three schedules, 30 Gy in 10 fractions 
(n = 93), 37.5 Gy in 15 fractions (n = 80) and 
40 Gy in 20 fractions (n = 74), were compared. 
Motor function was evaluated on a 6-point 
scale before and at the end of RT and 3, 6 and 
12 months later. A multivariate analysis was 
performed for functional outcome, including 
fractionation schedule and the three relevant 
prognostic factors (primary tumour type, time 
of developing motor defi cits before RT and am-
bulatory status). No signifi cant difference was 
observed for post-treatment motor function or 
ambulatory rates among the three schedules. 
According to the multivariate analysis, the 
radiation schedule had no signifi cant impact 
on functional outcome (p = 0.223) in contrast 
to the three prognostic factors (p <0.001, p 
<0.001 and p = 0.012). The three fractionation 
schedules were comparable for functional out-
come. The least time-consuming schedule (30 
Gy in 10 fractions) should be considered for 
patients with a markedly reduced life expec-
tancy.
Rades et al. (2005) investigated a reduction 
of the overall treatment time to only one day 
by comparing 1 x 8 Gy in multi-fractionated 
10 x 3 Gy for functional outcome. Data of 204 
patients, treated for MSCC with either 1 x 8 
Gy (n = 96) or 10 x 3 (n = 108), were analyzed 
retrospectively. Motor function and ambula-
tory status were evaluated before and up to 
24 weeks after RT. A multivariate analysis 
(nominal regression) was performed includ-
ing radiation schedule, performance status, 
age, irradiated vertebra and relevant prognos-
tic factors (histology, ambulatory status, time 
of developing motor defi cits). Improvement of 
motor defi cits was selected as the basic cat-
egory and compared with no change and dete-
rioration. Univariate analysis showed no sig-
nifi cant difference between the schedules for 
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post-treatment motor function and ambulato-
ry rates. Multivariate analysis demonstrated 
a signifi cant effect on functional outcome for 
the prognostic factors, but not for the radiation 
schedule (p = 0.853 for no change, p = 0.237 
for deterioration). Their data suggested the 
two fractionation schedules to be comparably 
effective for functional outcome. Thus, 1 x 8 
Gy should be considered for patients with a 
poor survival prognosis.
Rades et al. (2005) investigated the feasibil-
ity and effectiveness of re-irradiation (re-RT) 
for in-fi eld recurrence of metastatic spinal cord 
compression after primary RT with 1 x 8 Gy 
or 5 x 4 Gy. A total of 62 patients, treated with 
1 x 8 Gy (n = 34) or 5 x 4 Gy (n = 28) between 
January 1995 and August 2003, received re-
RT for in-fi eld recurrence of metastatic spinal 
cord compression. The median time to recur-
rence was 6 months (range, 2-40 months). Re-
RT was performed with 1 x 8 Gy (after 1 x 8 
Gy or 5 x 4 Gy, n = 34), 5 x 3 Gy (after 1 x 8 
Gy or 5 x 4 Gy, n = 15) or 5 x 4 Gy (after 1 x 8 
Gy, n = 13). The cumulative biologically effec-
tive dose (primary RT plus re-RT) was 80-100 
Gy2. The median follow-up after re-RT was 8 
months (range, 2-42 months). Motor function 
was evaluated up to 6 months after re-RT. Af-
ter re-RT, 25 patients (40%) showed improved 
motor function, 28 (45%) had no change and 9 
(15%) had deterioration. Of the 16 previously 
non-ambulatory patients, 6 (38%) regained the 
ability to walk. No second in-fi eld recurrence 
in the same spinal region was observed after 
re-RT. The outcome was not signifi cantly in-
fl uenced by the radiation schedule. Radiation 
myelopathy was not observed. Spinal re-RT 
with 1 x 8 Gy, 5 x 3 Gy or 5 x 4 Gy for in-fi eld 
recurrence of metastatic spinal cord compres-
sion appears safe and effective. Myelopathy 
seems unlikely, if the cumulative biologically 
effective dose is ≤ 100 Gy2.
CONCLUSION
The concept that RT alone could be the initial 
treatment for the majority of MSCC patients 
Author Steroids RT fractionation
Response (%) Median 
survival 
months
Median 
response 
months
Back Pain Motor 
dysfunction
Bladder 
dysfunction
Maranzano 
(1995)
Methylpred nisolone 
1g/day
Dexametha sone 
16 mg/d
5 Gy x 3
4 day rest
3 Gy x 5
82 76 44 6 8
Maranzano
(1997)
Dexamatha sone
8 mg x 2/d
8 Gy x 1
1 wk rest
8 Gy x 1 67 63 44 5 7
Maranzano
(2005)
Dexametha sone
8 mg x 2/d
8 Gy x 1
1 Wk rest
8 Gy x 1
5 Gy x 3
4 day rest
3 Gy x 5
56
59
68
71
90
89
4
4
3.5
3.5
Rades
(2002)
Dexametha sone 30 Gy/ 10 Fr
37.5 Gy/
15 Fr.
40 Gy /
5 Fr
55
61
56
Rades 
(2005)
Dexametha sone 8 Gy x 1
3 Gy x 10
45
41
Table 1. A review of studies comparing treatments with clinical outcome
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is largely accepted. However, tailored surgery 
(laminectomy or more often decompression 
and stabilization of the spine) plus RT must be 
performed in selected cases. With the excep-
tion of a few protocols, the use of conventional 
RT (daily fractions of 2 Gy to a total dose of 
30–40 Gy) has been abandoned in favour of 
RT regimens requiring a few or a number of 
fractions. Most patients with MSCC have a life 
expectancy of only several months. In these 
patients one radiotherapeutic schedule with a 
short overall treatment time would be the best 
option, if its effect on the most relevant clini-
cal symptoms, pain and motor dysfunction, is 
comparable to the effect of more protracted 
schedules. In patients with a reduced life ex-
pectancy, a radiotherapeutic effect on recal-
cifi cation, which can be expected only several 
months after RT, is of minor importance. In 
patients with a life expectancy of more than 
a few months, recalcifi cation becomes more 
of an issue and a more fractionated radiation 
schedule should be considered.
REFERENCES
1.  Rades D., Heidenreich F., Karstens J.H., Final 
results of a prospective study of the prognostic 
values of the time to develop motor defi cits be-
fore irradiation in metastatic spinal cord com-
pression. Int. Jr. Radiat Oncol. Biol. Phy. 53: 
975–979, 2002.
2. Larsen S.H., Sorensen P.S., Kreiner S., Prognos-
tic Factors in metastatic spinal cord compres-
sion – A prospective study using multivariate 
analysis of variables infl uencing survival and 
gait function in 153 patients. Int. Jr. Radiat, On-
col Biol. Phy. 46: 1163–1169, 2000.
3. Levivov M., Dall J., Stein M., Shahar M.B., Ar-
ush M.B., Milstein D., Goldsher D., Kuten A., 
The Management of metastatic spinal cord. 
Compression – A radiotherapeutic success ceil-
ing. Int. Jr. Radiat.  Oncol. Biol. Phy. 27: 231–234, 
1993.
4. Maranzono E., Latini P., Effectiveness of radia-
tion therapy without surgery in metastatic spinal 
cord compression : Final results from a prospec-
tive trial. Int. Jr. Radiat. Oncol. Biol. Phy 32: 
959–967, 1995.
5. Maranzomo E., Latini P., Perrucci E., Benevanti 
S., Lupattelli M., Corgna E., Short course radio-
therapy (8 Gy x 2) in metastatic spinal cord com-
pression – An effective and feasible treatment. 
Int. Jr. Radiat, Oncol. Biol. Phy. 38: 1037–1044, 
1997.
6. Maranzano E., Bellavita R., Rossi R., Angelis 
V.D., Frattegrani A., Bagnoli R., Mignogna M., 
Beneventi S., Lupatelli M., Panticelli P., Biti 
G.P., Latini P., Short course versus split course 
radiotherapy in metastatic spinal cord compres-
sion : Results for a phase III randomized multi 
center trial. Jr. Clin. Oncol. 23: 3358–3365, 
2005.
7. Rades D., Karstens J.H. Alberti W., Role of ra-
diotherapy in the treatment of motor dysfunc-
tion due to metastatic spinal cord compression: 
compression of three different fractionation 
schedules. Int. Jr. Radiat. Oncol. Biol. Phy. 54: 
1160–1164, 2002.
8. Rades D., Stalpers L.J.A. Hulshof M.C., Borg-
mann K., Karstons J.H., Koning C.C.E., Alberti 
W., Comparison of 1x8 Gy and 10x3 Gy for func-
tional outcome in patients with metastatic spinal 
cord compression. Int. Jr. Radiat, Oncol. Biol. 
Phy. 62: 514–518, 2005.
9. Rades D., Stalpers L.J.A., Veninga T., Hoskin 
P.J., Spinal reirradiation after short course RT 
for metastatic spinal cord Compression. Int. Jr. 
Radiat, Oncol. Biol. Phy. 63: 872–875, 2005.
Book 1.indb   149 2008-10-14   11:50:57
